ADG106 / Adagene 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), ADG106 / Adagene
    Enrollment open, Metastases:  ComPACT: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (clinicaltrials.gov) -  Jul 20, 2023   
    P1b,  N=51, Recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1 | Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Jul 2024 Not yet recruiting --> Recruiting
  • ||||||||||  ADG106 / Adagene
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma (clinicaltrials.gov) -  Apr 24, 2023   
    P1/2,  N=25, Terminated, 
    Not yet recruiting --> Recruiting N=60 --> 25 | Trial completion date: Feb 2024 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2023 --> Feb 2023; The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered.
  • ||||||||||  ADG116 / Adagene, ADG106 / Adagene
    Phase classification, Enrollment change, Metastases:  ADG116-1003: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients (clinicaltrials.gov) -  Apr 24, 2023   
    P1b/2,  N=77, Recruiting, 
    N=60 --> 25 | Trial completion date: Feb 2024 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2023 --> Feb 2023; The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered. Phase classification: P1b --> P1b/2 | N=204 --> 77
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), ADG106 / Adagene
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  ComPACT: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (clinicaltrials.gov) -  Nov 3, 2022   
    P1b,  N=51, Not yet recruiting, 
    Phase classification: P1 --> P1/2 | N=146 --> 91 Trial completion date: Oct 2026 --> Dec 2026 | Initiation date: Oct 2022 --> Dec 2022 | Trial primary completion date: Oct 2025 --> Dec 2025
  • ||||||||||  ADG106 / Adagene
    Trial completion date, Trial primary completion date, Metastases:  ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jul 25, 2022   
    P1,  N=62, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2021 --> Jan 2022 Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Feb 2022 --> Nov 2021
  • ||||||||||  ADG106 / Adagene
    Trial primary completion date, Metastases:  ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jan 12, 2022   
    P1,  N=62, Active, not recruiting, 
    Phase classification: P1 --> P1b | N=60 --> 204 | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Jul 2023 Trial primary completion date: Aug 2021 --> Feb 2022
  • ||||||||||  ADG106 / Adagene
    Enrollment closed, Enrollment change, Trial primary completion date, Metastases:  ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov) -  May 12, 2021   
    P1,  N=62, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Apr 2021 --> Aug 2021 Recruiting --> Active, not recruiting | N=24 --> 62 | Trial primary completion date: Apr 2021 --> Aug 2021
  • ||||||||||  ADG-106 / Adagene
    A safe and potent agonist ADG106 targeting a unique epitope of CD137 with novel mechanism of actions (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_1549;    
    Mechanistic analyses suggest that ADG106 stimulates tumor infiltration and expansion of CD4+ and CD8+ T cells, thereby promoting the antitumor responses. These findings support that ADG106-boosted immune response could offer an effective but alternative solution for cancer immunotherapy in single and combination therapies, especially for non-responders to current PD-1/PD-L1 based immunotherapies.